Analytical Data
-
Gene name
Wilms tumor protein/WT1
- Application
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P22561
-
Expression Region
1-449aa
-
Molecular Weight
56.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Wilms tumor protein (WT1) is a crucial transcription factor initially identified in the context of Wilms tumor, a pediatric kidney cancer. Its gene, located on chromosome 11p13, plays a significant role in kidney and gonadal development. Mutations or abnormal expression of WT1 are linked to various syndromes, including WAGR syndrome and Denys-Drash syndrome, both associated with increased risk of Wilms tumor and other developmental disorders. The study of WT1 has expanded beyond oncology to include its involvement in stem cell biology, hematopoiesis, and organogenesis. Recombinant WT1 protein is instrumental in elucidating its functional properties and regulatory mechanisms, providing insights into its role in tumorigenesis and normal development. Researchers utilize recombinant WT1 in various applications, including immunotherapy, where it is explored as a target for vaccines against Wilms tumor and other cancers. Understanding the precise interactions and pathways mediated by WT1 could lead to novel therapeutic strategies and improve clinical outcomes for patients with malignancies associated with WT1 dysregulation. Thus, the production and study of recombinant WT1 protein continue to be a priority in cancer research, emphasizing its potential as both a biomarker and therapeutic target.
